Delivery Order SPE2DB24D2010-SPE2DB25FABBZ
- Not listed
- The Defense Logistics Agency awarded a $36,425.77 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40mg/4ml (2 units) under a firm fixed price contract. This delivery order, issued on October 27, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been selected to fulfill this medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL auto-injectors, with a ceiling value of $3,992.42 and completion deadline of June 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under the company's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $3,979.90 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL units, with an ultimate completion date of December 1, 2025. This non-competitive delivery order represents a firm fixed-price transaction under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be performed at the vendor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $10,030.26, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, represents a competitive award with no set-aside designation and a completion date of August 6, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a $2,265.90 delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of HUMIRA (Adalimumab) pen injectors at a strength of 40 mg/0.4 mL. This competitive award, which has no set-aside designation, represents a firm fixed-price delivery order with an ultimate completion date of November 3, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL autoinjectors under a firm fixed-price contract valued at $5,800.58. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by November 25, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pen injections, valued at $2,387.94 under a firm fixed-price arrangement. The award, effective November 18, 2025, with completion targeted for November 19, 2025, represents a non-competitive delivery order utilizing existing contract authority. AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania serves as the place of performance for this...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for HUMIRA Pen 40 mg/0.8 mL, valued at $1,574.50 under a firm fixed-price contract. The award was made on June 25, 2025, with an ultimate completion date of June 26, 2025. This non-set-aside contract is a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Performance of this delivery...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABBZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at approximately $26,000 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) PEN 40 mg/0.4 mL auto-injectors. This firm fixed-price delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a leading pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The parent IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a comprehensive range of medications, vaccines, and medical supplies to support military healthcare programs and other federal medical systems worldwide. HUMIRA, a brand-name biologic immunosuppressant used primarily for autoimmune conditions, exemplifies the specialized pharmaceutical products delivered through this contract vehicle to support Defense Health Agency requirements and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.0k | 9/5/25 |